Every 8-K that Sunshine Biopharma Inc (SBFM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SBFM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBFM filings page.
Sunshine Biopharma Inc. (SBFM) reported that on August 25, 2026, director Dr. Andrew Keller informed the company he will not seek or accept reelection to the Board of Directors after his current term ends. His term will expire at the company’s next annual shareholder meeting, at which point he will leave the board.
Sunshine Biopharma Inc. reports that, as a result of recent sales of its common stock under a previously disclosed at-the-market offering, the exercise price of its outstanding Series B Warrants has been reduced to $1.2202. This exercise price remains subject to further adjustment under the terms of the Series B Warrants.
Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp., allowing the company to sell shares of its common stock from time to time for an aggregate offering price of up to $4,000,000 in at-the-market offerings through or to Aegis as exclusive sales agent.
Sales may be effected directly on or through the Nasdaq Capital Market or other existing trading markets under Rule 415(a)(4). Aegis will receive a 3.0% commission on gross proceeds plus certain reimbursed expenses. Neither party is obligated to transact, and both may terminate the agreement. The shares will be issued under the company’s shelf registration statement on Form S-3 (File No. 333-284142), effective January 15, 2025, and a July 20, 2026 prospectus supplement.
Sunshine Biopharma Inc., through its wholly owned subsidiary Nora Pharma Inc., entered into an agreement of transaction and mutual release with Nora’s former president, Malek Chamoun, on July 8, 2026. Under this agreement, Sunshine Biopharma agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties. The agreement functions as a comprehensive release, aiming to conclude outstanding claims between the company, Nora, and Mr. Chamoun.
Sunshine Biopharma Inc. reports that its majority stockholder, CEO Dr. Steve N. Slilaty, approved by written consent several actions tied to the company’s recent public offering that closed on May 19, 2026. The approval covers issuing more than twenty percent of the outstanding common shares at a deemed discount to the Nasdaq Minimum Price and allows certain exercise price and share-count adjustments for Series C Warrants in connection with a Share Combination Event or voluntary exercise price changes. The consent becomes effective 20 days after a definitive information statement is mailed to stockholders, with Dr. Slilaty holding approximately 86% of the total voting power.
Sunshine Biopharma Inc. completed a best efforts public unit offering, raising approximately $6.0 million in gross proceeds through 12,000,000 Common Units or Pre-Funded Units priced at $0.50 per Common Unit.
Each unit includes one share of common stock or one Pre-Funded Warrant plus two Series C Warrants, each Series C Warrant exercisable at $0.50 per share for five years. The Pre-Funded Warrants are immediately exercisable at $0.00001 per share until fully exercised. If all Series C Warrants are exercised on a cash basis, the Company could receive up to an additional approximately $12.0 million in gross proceeds.
The Company intends to use net proceeds for general corporate purposes and working capital, supporting its Canadian generic drug portfolio and proprietary programs in liver cancer and SARS-related coronavirus infections.
Sunshine Biopharma Inc. reported 2025 revenue of $36.3 million, a 4.1% increase from 2024, as it expanded its generic drug portfolio and advanced proprietary R&D programs. Gross profit rose to $12.26 million, while general and administrative expenses increased to $18.48 million, including a non-cash, non-recurring $1.75 million impairment charge on intangible assets.
The company recorded a net loss of $5.98 million for 2025, slightly higher than 2024. It raised $2.46 million in gross proceeds through a registered direct offering to support sales expansion and launched nine new generic prescription drugs. Management implemented cost-reduction initiatives in January 2026, which are expected to lower expenses by about $2 million to $3 million in 2026 as it works toward near-term profitability.
Sunshine Biopharma Inc. engaged Aegis Capital Corp. as its warrant solicitation agent to encourage holders to exercise the Company’s outstanding warrants. Aegis will act on a “best efforts” basis for a three-month term and receive a fee equal to 10% of gross proceeds from any warrant exercises during this period, plus reimbursed expenses.
The engagement letter includes customary indemnification and contribution provisions under which the Company agrees to cover certain losses, liabilities and expenses of Aegis and related parties, subject to limits tied to Aegis’ commissions and carve-outs for gross negligence, willful misconduct and fraudulent misrepresentation.
Sunshine Biopharma Inc. reported that its majority voting stockholder, Dr. Steve N. Slilaty, has approved a potential reverse split of the company’s issued and outstanding common stock at a ratio of up to 1-for-10. The board of directors has discretion whether to implement the reverse split and to set the exact whole-number ratio within that range. The shareholder consent will become effective 20 days after a definitive information statement is mailed to stockholders. Dr. Slilaty, the company’s chief executive officer, holds approximately 96% of the total voting power of the company’s stockholders.
Sunshine Biopharma Inc. reported that on February 5, 2026, Dr. Abderrazzak Merzouki resigned from his position as chief operating officer, effective immediately. The filing does not describe any changes to other executive roles, and it is signed by Chief Executive Officer Dr. Steve N. Slilaty on behalf of the company.
Sunshine Biopharma Inc. reported the results of its annual stockholder meeting held on December 11, 2025. Stockholders elected five directors — including Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller — to serve until the next annual meeting or until successors are elected and qualified.
Shareholders also ratified the appointment of M&K CPAS, PLLC as the company’s independent registered public accounting firm for 2025. In addition, they approved an amendment to the 2023 Equity Incentive Plan, increasing the number of common shares authorized for issuance under the plan to 683,000, providing additional equity available for future employee and director compensation awards.
Sunshine Biopharma Inc. reported a change in its independent auditor. Effective September 24, 2025, the company dismissed Bush & Associates CPA LLC as its independent registered public accounting firm and engaged M&K CPAS, PLLC as its new auditor. The board of directors and audit committee approved this decision by unanimous consent.
The company states that for the fiscal years ended December 31, 2023 and 2024, and through September 24, 2025, there were no disagreements with Bush & Associates on accounting principles, financial statement disclosure, or audit procedures, and no reportable events under SEC rules. Bush & Associates’ prior audit reports did not contain adverse opinions, disclaimers, or qualifications. Sunshine Biopharma has requested a letter from Bush & Associates to the SEC regarding these disclosures and plans to file it by amendment once received.